Company Overview of Opus Bio, Inc.
Opus Bio, Inc. develops and commercializes lentiviral gene delivery products for human diseases for therapeutic, vaccine, and bioproduction applications. The company’s product pipeline includes treatment for chronic lymphocytic leukemia, glioblastoma, melanoma, and hemophilia A; vaccine preclinical programs and vaccine candidates, including virus like particles vaccines that target pandemic and seasonal influenza, Hepatitis C virus infection, and HIV/AIDS; and protein therapeutics that include the production of erythropoietin and factor VIII. It also has various programs on various stem cell types, such as hematopoietic (or blood making) stem cells (HSC) for the treatment of cancer and chron...
910 Clopper Road
Suite 200 South
Gaithersburg, MD 20878
Founded in 2004
Key Executives for Opus Bio, Inc.
Chief Executive Officer and Director
Vice President of Vector Development
Director of Business Planning
Director of Research & Development
Director of Quality Control
Compensation as of Fiscal Year 2015.
Opus Bio, Inc. Key Developments
Juno Therapeutics Partners with Opus Bio
Dec 9 14
Juno Therapeutics, Inc. entered into an agreement to obtain a license from Opus Bio, Inc. (formerly Lentigen Corporation) for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. Both the companies are based in the US.
Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013
Sep 28 13
Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013 . Venue: New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries